Pharma

Your Article Summary

See Latest Articles

Enzon reports 2nd quarter 2009 results
Enzon Pharmaceuticals, 08/19/09

Enzon Pharmaceuticals, Inc. announced its financial results for the second quarter of 2009. For the three months ended June 2009, Enzon reported a net loss of $5.1 million or $0.11 per diluted share, as compared to a net loss of $1.7 million or $0.04 per diluted share for the second quarter of 2008. The 2009 financial results were impacted by the anticipated investment in R and D including PEG–SN38 and the next–generation Oncaspar program, as well as lower royalty and contract manufacturing revenues.

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Bristol-Myers Squibb Sets Exchange Ratio of 0.6313 for the Exchange Offer
Bristol Myers-Squibb Company, 12/17/09

Abbott Declares 344th Consecutive Quarterly Dividend
Abbott, 12/15/09

Pre-Budget Report response - GSK comments on patent box
GlaxoSmithKline, 12/11/09

 See all of Financial Reports